Ligand Pharmaceuticals (NASDAQ:LGND) Stock Rating Reaffirmed by Benchmark themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) – Investment analysts at Zacks Research lowered their FY2023 earnings per share estimates for Ligand Pharmaceuticals in a note issued to investors on Tuesday, November 28th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $4.13 for the year, down […]
Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have received an average rating of “Buy” from the four brokerages that are covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $109.75 Average Target Price from Analysts etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
American International Group Inc. boosted its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 7.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,937 shares of the biotechnology company’s stock after buying an additional 622 shares during the quarter. […]